LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: A machine learning-based approach to determine infection status in recipients of BBV152 (Covaxin) whole-virion inactivated SARS-CoV-2 vaccine for serological surveys.

    Singh, Prateek / Ujjainiya, Rajat / Prakash, Satyartha / Naushin, Salwa / Sardana, Viren / Bhatheja, Nitin / Singh, Ajay Pratap / Barman, Joydeb / Kumar, Kartik / Gayali, Saurabh / Khan, Raju / Rawat, Birendra Singh / Tallapaka, Karthik Bharadwaj / Anumalla, Mahesh / Lahiri, Amit / Kar, Susanta / Bhosale, Vivek / Srivastava, Mrigank / Mugale, Madhav Nilakanth /
    Pandey, C P / Khan, Shaziya / Katiyar, Shivani / Raj, Desh / Ishteyaque, Sharmeen / Khanka, Sonu / Rani, Ankita / Promila / Sharma, Jyotsna / Seth, Anuradha / Dutta, Mukul / Saurabh, Nishant / Veerapandian, Murugan / Venkatachalam, Ganesh / Bansal, Deepak / Gupta, Dinesh / Halami, Prakash M / Peddha, Muthukumar Serva / Veeranna, Ravindra P / Pal, Anirban / Singh, Ranvijay Kumar / Anandasadagopan, Suresh Kumar / Karuppanan, Parimala / Rahman, Syed Nasar / Selvakumar, Gopika / Venkatesan, Subramanian / Karmakar, Malay Kumar / Sardana, Harish Kumar / Kothari, Anamika / Parihar, Devendra Singh / Thakur, Anupma / Saifi, Anas / Gupta, Naman / Singh, Yogita / Reddu, Ritu / Gautam, Rizul / Mishra, Anuj / Mishra, Avinash / Gogeri, Iranna / Rayasam, Geethavani / Padwad, Yogendra / Patial, Vikram / Hallan, Vipin / Singh, Damanpreet / Tirpude, Narendra / Chakrabarti, Partha / Maity, Sujay Krishna / Ganguly, Dipyaman / Sistla, Ramakrishna / Balthu, Narender Kumar / A, Kiran Kumar / Ranjith, Siva / Kumar, B Vijay / Jamwal, Piyush Singh / Wali, Anshu / Ahmed, Sajad / Chouhan, Rekha / Gandhi, Sumit G / Sharma, Nancy / Rai, Garima / Irshad, Faisal / Jamwal, Vijay Lakshmi / Paddar, Masroor Ahmad / Khan, Sameer Ullah / Malik, Fayaz / Ghosh, Debashish / Thakkar, Ghanshyam / Barik, S K / Tripathi, Prabhanshu / Satija, Yatendra Kumar / Mohanty, Sneha / Khan, Md Tauseef / Subudhi, Umakanta / Sen, Pradip / Kumar, Rashmi / Bhardwaj, Anshu / Gupta, Pawan / Sharma, Deepak / Tuli, Amit / Ray Chaudhuri, Saumya / Krishnamurthi, Srinivasan / Prakash, L / Rao, Ch V / Singh, B N / Chaurasiya, Arvindkumar / Chaurasiyar, Meera / Bhadange, Mayuri / Likhitkar, Bhagyashree / Mohite, Sharada / Patil, Yogita / Kulkarni, Mahesh / Joshi, Rakesh / Pandya, Vaibhav / Mahajan, Sachin / Patil, Amita / Samson, Rachel / Vare, Tejas / Dharne, Mahesh / Giri, Ashok / Paranjape, Shilpa / Sastry, G Narahari / Kalita, Jatin / Phukan, Tridip / Manna, Prasenjit / Romi, Wahengbam / Bharali, Pankaj / Ozah, Dibyajyoti / Sahu, Ravi Kumar / Dutta, Prachurjya / Singh, Moirangthem Goutam / Gogoi, Gayatri / Tapadar, Yasmin Begam / Babu, Elapavalooru Vssk / Sukumaran, Rajeev K / Nair, Aishwarya R / Puthiyamadam, Anoop / Valappil, Prajeesh Kooloth / Pillai Prasannakumari, Adrash Velayudhan / Chodankar, Kalpana / Damare, Samir / Agrawal, Ved Varun / Chaudhary, Kumardeep / Agrawal, Anurag / Sengupta, Shantanu / Dash, Debasis

    Computers in biology and medicine

    2022  Volume 146, Page(s) 105419

    Abstract: Data science has been an invaluable part of the COVID-19 pandemic response with multiple applications, ranging from tracking viral evolution to understanding the vaccine effectiveness. Asymptomatic breakthrough infections have been a major problem in ... ...

    Abstract Data science has been an invaluable part of the COVID-19 pandemic response with multiple applications, ranging from tracking viral evolution to understanding the vaccine effectiveness. Asymptomatic breakthrough infections have been a major problem in assessing vaccine effectiveness in populations globally. Serological discrimination of vaccine response from infection has so far been limited to Spike protein vaccines since whole virion vaccines generate antibodies against all the viral proteins. Here, we show how a statistical and machine learning (ML) based approach can be used to discriminate between SARS-CoV-2 infection and immune response to an inactivated whole virion vaccine (BBV152, Covaxin). For this, we assessed serial data on antibodies against Spike and Nucleocapsid antigens, along with age, sex, number of doses taken, and days since last dose, for 1823 Covaxin recipients. An ensemble ML model, incorporating a consensus clustering approach alongside the support vector machine model, was built on 1063 samples where reliable qualifying data existed, and then applied to the entire dataset. Of 1448 self-reported negative subjects, our ensemble ML model classified 724 to be infected. For method validation, we determined the relative ability of a random subset of samples to neutralize Delta versus wild-type strain using a surrogate neutralization assay. We worked on the premise that antibodies generated by a whole virion vaccine would neutralize wild type more efficiently than delta strain. In 100 of 156 samples, where ML prediction differed from self-reported uninfected status, neutralization against Delta strain was more effective, indicating infection. We found 71.8% subjects predicted to be infected during the surge, which is concordant with the percentage of sequences classified as Delta (75.6%-80.2%) over the same period. Our approach will help in real-world vaccine effectiveness assessments where whole virion vaccines are commonly used.
    MeSH term(s) COVID-19/epidemiology ; COVID-19/prevention & control ; COVID-19 Vaccines/therapeutic use ; Humans ; Machine Learning ; Pandemics ; SARS-CoV-2 ; Vaccines, Inactivated ; Viral Vaccines ; Virion
    Chemical Substances COVID-19 Vaccines ; Vaccines, Inactivated ; Viral Vaccines
    Language English
    Publishing date 2022-04-25
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 127557-4
    ISSN 1879-0534 ; 0010-4825
    ISSN (online) 1879-0534
    ISSN 0010-4825
    DOI 10.1016/j.compbiomed.2022.105419
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2.

    Naushin, Salwa / Sardana, Viren / Ujjainiya, Rajat / Bhatheja, Nitin / Kutum, Rintu / Bhaskar, Akash Kumar / Pradhan, Shalini / Prakash, Satyartha / Khan, Raju / Rawat, Birendra Singh / Tallapaka, Karthik Bharadwaj / Anumalla, Mahesh / Chandak, Giriraj Ratan / Lahiri, Amit / Kar, Susanta / Mulay, Shrikant Ramesh / Mugale, Madhav Nilakanth / Srivastava, Mrigank / Khan, Shaziya /
    Srivastava, Anjali / Tomar, Bhawana / Veerapandian, Murugan / Venkatachalam, Ganesh / Vijayakumar, Selvamani Raja / Agarwal, Ajay / Gupta, Dinesh / Halami, Prakash M / Peddha, Muthukumar Serva / Sundaram, Gopinath M / Veeranna, Ravindra P / Pal, Anirban / Agarwal, Vinay Kumar / Maurya, Anil Ku / Singh, Ranvijay Kumar / Raman, Ashok Kumar / Anandasadagopan, Suresh Kumar / Karuppanan, Parimala / Venkatesan, Subramanian / Sardana, Harish Kumar / Kothari, Anamika / Jain, Rishabh / Thakur, Anupama / Parihar, Devendra Singh / Saifi, Anas / Kaur, Jasleen / Kumar, Virendra / Mishra, Avinash / Gogeri, Iranna / Rayasam, Geethavani / Singh, Praveen / Chakraborty, Rahul / Chaturvedi, Gaura / Karunakar, Pinreddy / Yadav, Rohit / Singhmar, Sunanda / Singh, Dayanidhi / Sarkar, Sharmistha / Bhattacharya, Purbasha / Acharya, Sundaram / Singh, Vandana / Verma, Shweta / Soni, Drishti / Seth, Surabhi / Vashisht, Sakshi / Thakran, Sarita / Fatima, Firdaus / Singh, Akash Pratap / Sharma, Akanksha / Sharma, Babita / Subramanian, Manikandan / Padwad, Yogendra S / Hallan, Vipin / Patial, Vikram / Singh, Damanpreet / Tripude, Narendra Vijay / Chakrabarti, Partha / Maity, Sujay Krishna / Ganguly, Dipyaman / Sarkar, Jit / Ramakrishna, Sistla / Kumar, Balthu Narender / Kumar, Kiran A / Gandhi, Sumit G / Jamwal, Piyush Singh / Chouhan, Rekha / Jamwal, Vijay Lakshmi / Kapoor, Nitika / Ghosh, Debashish / Thakkar, Ghanshyam / Subudhi, Umakanta / Sen, Pradip / Chaudhury, Saumya Ray / Kumar, Rashmi / Gupta, Pawan / Tuli, Amit / Sharma, Deepak / Ringe, Rajesh P / D, Amarnarayan / Kulkarni, Mahesh / Shanmugam, Dhansekaran / Dharne, Mahesh S / Dastager, Sayed G / Joshi, Rakesh / Patil, Amita P / Mahajan, Sachin N / Khan, Abujunaid Habib / Wagh, Vasudev / Yadav, Rakesh Kumar / Khilari, Ajinkya / Bhadange, Mayuri / Chaurasiya, Arvindkumar H / Kulsange, Shabda E / Khairnar, Krishna / Paranjape, Shilpa / Kalita, Jatin / Sastry, Narahari G / Phukan, Tridip / Manna, Prasenjit / Romi, Wahengbam / Bharali, Pankaj / Ozah, Dibyajyoti / Sahu, Ravi Kumar / Babu, Elapavalooru Vssk / Sukumaran, Rajeev / Nair, Aiswarya R / Valappil, Prajeesh Kooloth / Puthiyamadam, Anoop / Velayudhanpillai, Adarsh / Chodankar, Kalpana / Damare, Samir / Madhavi, Yennapu / Aggarwal, Ved Varun / Dahiya, Sumit / Agrawal, Anurag / Dash, Debasis / Sengupta, Shantanu

    eLife

    2021  Volume 10

    Abstract: To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested ...

    Abstract To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value: 2.23, 1.92-2.59, <0.0001), use of public transport (1.79, 1.43-2.24, <0.0001), not smoking (1.52, 1.16-1.99, 0.0257), non-vegetarian diet (1.67, 1.41-1.99, <0.0001), and B blood group (1.36, 1.15-1.61, 0.001).
    MeSH term(s) Antibodies, Neutralizing/blood ; Antibodies, Viral/blood ; Biomarkers/blood ; COVID-19/diagnosis ; COVID-19/epidemiology ; COVID-19/immunology ; COVID-19/virology ; COVID-19 Serological Testing ; Female ; Host-Pathogen Interactions ; Humans ; Immunity, Humoral ; India/epidemiology ; Longitudinal Studies ; Male ; Predictive Value of Tests ; Risk Assessment ; Risk Factors ; SARS-CoV-2/immunology ; Seroepidemiologic Studies ; Time Factors
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; Biomarkers
    Language English
    Publishing date 2021-04-20
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 2687154-3
    ISSN 2050-084X ; 2050-084X
    ISSN (online) 2050-084X
    ISSN 2050-084X
    DOI 10.7554/eLife.66537
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A machine learning-based approach to determine infection status in recipients of BBV152 whole virion inactivated SARS-CoV-2 vaccine for serological surveys

    Singh, Prateek / Ujjainiya, Rajat / Prakash, Satyartha / Naushin, Salwa / Sardana, Viren / Bhatheja, Nitin / Singh, Ajay Pratap / Barman, Joydeb / Kumar, Kartik / Khan, Raju / Tallapaka, Karthik Bharadwaj / Anumalla, Mahesh / Lahiri, Amit / Kar, Susanta / Bhosale, Vivek / Srivastava, Mrigank / Mugale, Madhav Nilakanth / Pandey, C.P / Khan, Shaziya /
    Katiyar, Shivani / Raj, Desh / Ishteyaque, Sharmeen / Khanka, Sonu / Rani, Ankita / Promila / Sharma, Jyotsna / Seth, Anuradha / Dutta, Mukul / Saurabh, Nishant / Veerapandian, Murugan / Venkatachalam, Ganesh / Bansal, Deepak / Gupta, Dinesh / Halami, Prakash M / Peddha, Muthukumar Serva / Sundaram, Gopinath M / Veeranna, Ravindra P / Pal, Anirban / Singh, Ranvijay Kumar / Anandasadagopan, Suresh Kumar / Karuppanan, Parimala / Rahman, Syed Nasar / Selvakumar, Gopika / Venkatesan, Subramanian / Karmakar, MalayKumar / Sardana, Harish Kumar / Kothari, Animika / Parihar, DevendraSingh / Thakur, Anupma / Saifi, Anas / Gupta, Naman / Singh, Yogita / Reddu, Ritu / Gautam, Rizul / Mishra, Anuj / Mishra, Avinash / Gogeri, Iranna / Rayasam, Geethavani / Padwad, Yogendra / Patial, Vikram / Hallan, Vipin / Singh, Damanpreet / Tirpude, Narendra / Chakrabarti, Partha / Maity, Sujay Krishna / Ganguly, Dipyaman / Sistla, Ramakrishna / Balthu, Narender Kumar / A, Kiran Kumar / Ranjith, Siva / Kumar, Vijay B / Jamwal, Piyush Singh / Wali, Anshu / Ahmed, Sajad / Chouhan, Rekha / Gandhi, Sumit G / Sharma, Nancy / Rai, Garima / Irshad, Faisal / Jamwal, Vijay Lakshmi / Paddar, MasroorAhmad / Khan, Sameer Ullah / Malik, Fayaz / Ghosh, Debashish / Thakkar, Ghanshyam / Barik, Saroj K / Tripathi, Prabhanshu / Satija, Yatendra Kumar / Mohanty, Sneha / Khan, Md. Tauseef / Subudhi, Umakanta / Sen, Pradip / Kumar, Rashmi / Bhardwaj, Anshu / Gupta, Pawan / Sharma, Deepak / Tuli, Amit / Chaudhuri, Saumya Ray / Krishnamurthi, Srinivasan / L, Prakash / Rao, Ch V / Singh, B N / Chaurasiya, Arvindkumar / Chaurasiyar, Meera / Bhadange, Mayuri / Likhitkar, Bhagyashree / Mohite, Sharada / Patil, Yogita / Kulkarni, Mahesh / Joshi, Rakesh / Pandya, Vaibhav / Patil, Amita / Samson, Rachel / Vare, Tejas / Dharne, Mahesh / Giri, Ashok / Paranjape, Shilpa / Sastry, G. Narahari / Kalita, Jatin / Phukan, Tridip / Manna, Prasenjit / Romi, Wahengbam / Bharali, Pankaj / Ozah, Dibyajyoti / Sahu, Ravi Kumar / Dutta, Prachurjya / Singh, Moirangthem Goutam / Gogoi, Gayatri / Tapadar, Yasmin Begam / Babu, Elapavalooru VSSK / Sukumaran, Rajeev K / Nair, Aishwarya R / Puthiyamadam, Anoop / Valappil, PrajeeshKooloth / Pillai Prasannakumari, Adrash Velayudhan / Chodankar, Kalpana / Damare, Samir / Agrawal, Ved Varun / Chaudhary, Kumardeep / Agrawal, Anurag / Sengupta, Shantanu / Dash, Debasis

    medRxiv

    Abstract: Data science has been an invaluable part of the COVID-19 pandemic response with multiple applications, ranging from tracking viral evolution to understanding the effectiveness of interventions. Asymptomatic breakthrough infections have been a major ... ...

    Abstract Data science has been an invaluable part of the COVID-19 pandemic response with multiple applications, ranging from tracking viral evolution to understanding the effectiveness of interventions. Asymptomatic breakthrough infections have been a major problem during the ongoing surge of Delta variant globally. Serological discrimination of vaccine response from infection has so far been limited to Spike protein vaccines used in the higher-income regions. Here, we show for the first time how statistical and machine learning (ML) approaches can discriminate SARS-CoV-2 infection from immune response to an inactivated whole virion vaccine (BBV152, Covaxin, India), thereby permitting real-world vaccine effectiveness assessments from cohort-based serosurveys in Asia and Africa where such vaccines are commonly used. Briefly, we accessed serial data on Anti-S and Anti-NC antibody concentration values, along with age, sex, number of doses, and number of days since the last vaccine dose for 1823 Covaxin recipients. An ensemble ML model, incorporating a consensus clustering approach alongside the support vector machine (SVM) model, was built on 1063 samples where reliable qualifying data existed, and then applied to the entire dataset. Of 1448 self-reported negative subjects, 724 were classified as infected. Since the vaccine contains wild-type virus and the antibodies induced will neutralize wild type much better than Delta variant, we determined the relative ability of a random subset of such samples to neutralize Delta versus wild type strain. In 100 of 156 samples, where ML prediction differed from self-reported uninfected status, Delta variant, was neutralized more effectively than the wild type, which cannot happen without infection. The fraction rose to 71.8% (28 of 39) in subjects predicted to be infected during the surge, which is concordant with the percentage of sequences classified as Delta (75.6%-80.2%) over the same period.
    Keywords covid19
    Language English
    Publishing date 2021-12-17
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.12.16.21267889
    Database COVID19

    Kategorien

  4. Article ; Online: Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2

    Naushin, Salwa / Sardana, Viren / Ujjainiya, Rajat / Bhatheja, Nitin / Kutum, Rintu / Bhaskar, Akash Kumar / Pradhan, Shalini / Prakash, Satyartha / Khan, Raju / Rawat, Birendra Singh / Chandak, Giriraj Ratan / Tallapaka, Karthik Bharadwaj / Anumalla, Mahesh / Lahiri, Amit / Kar, Susanta / Mulay, Shrikant Ramesh / Mugale, Madhav Nilakanth / Srivastava, Mrigank / Khan, Shaziya /
    Srivastava, Anjali / Tomar, Bhawna / Veerapandian, Murugan / Venkatachalam, Ganesh / Vijayakumar, Selvamani Raja / Agarwal, Ajay / Gupta, Dinesh / Halami, Prakash M / Peddha, Muthukumar Serva / M, Gopinath / Veeranna, Ravindra P / Pal, Anirban / Agarwal, Vinay Kumar / Maurya, Anil Ku / Singh, Ranvijay Kumar / Raman, Ashok Kumar / Anandasadagopan, Suresh Kumar / Karupannan, Parimala / Venkatesan, Subramanian / Sardana, Harish Kumar / Kothari, Anamika / Jain, Rishabh / Thakur, Anupma / Parihar, Devendra Singh / Saifi, Anas / Kaur, Jasleen / Kumar, Virendra / Mishra, Avinash / Gogeri, Iranna / Rayasam, Geetha Vani / Singh, Praveen / Chakraborty, Rahul / Chaturvedi, Gaura / Karunakar, Pinreddy / Yadav, Rohit / Singhmar, Sunanda / Singh, Dayanidhi / Sarkar, Sharmistha / Bhattacharya, Purbasha / Acharya, Sundaram / Singh, Vandana / Verma, Shweta / Soni, Drishti / Seth, Surabhi / Fatima, Firdaus / Vashisht, Shakshi / Thakran, Sarita / Singh, Akash Pratap / Sharma, Akanksha / Sharma, Babita / Subramanian, Manikandan / Padwad, Yogendra / Hallan, Vipin / Patial, Vikram / Singh, Damanpreet / Tirpude, Narendra Vijay / Chakrabarti, Partha / Maity, Sujay Krishna / Ganguly, Dipyaman / Sarkar, Jit / Ramakrishna, Sistla / Kumar, Balthu Narender / Kumar, Kiran A / Gandhi, Sumit G. / Jamwal, Piyush Singh / Chouhan, Rekha / Jamwal, Vijay Lakshmi / Kapoor, Nitika / Ghosh, Debashish / Thakkar, Ghanshyam / Subudhi, Umakanta / Sen, Pradip / Raychaudhri, Saumya / Tuli, Amit / Gupta, Pawan / Kumar, Rashmi / Sharma, Deepak / Ringe, Rajesh P. / D, Amarnarayan / Kulkarni, Mahesh / Shanmugam, Dhanasekaran / Dharne, Mahesh / Dastager, Syed G / Joshi, Rakesh / Patil, Amita P. / Mahajan, Sachin N / Khan, Abu Junaid / Wagh, Vasudev / Yadav, Rakeshkumar / Khilari, Ajinkya / Bhadange, Mayuri / Chaurasiya, Arvindkumar H. / Kulsange, Shabda E / khairnar, Krishna / Paranjape, Shilpa / Kalita, Jatin / Sastry, G.Narahari / Phukan, Tridip / Manna, Prasenjit / Romi, Wahengbam / Bharali, Pankaj / Ozah, Dibyajyoti / Sahu, Ravi Kumar / Babu, Elapaval VSSK / Sukumaran, Rajeev K / Nair, Aishwarya R / Puthiyamadam, Anoop / Valappil, Prajeesh Kooloth / Velayudhanpillai, Adarsh / Chodankar, Kalpana / Damare, Samir / Madhavi, Yennapu / Agrawal, Ved Varun / Dahiya, Sumit / Agrawal, Anurag / Dash, Debasis / Sengupta, Shantanu

    medRxiv

    Abstract: Background: India has been amongst the most affected nations during the SARS CoV2 pandemic, with sparse data on country wide spread of asymptomatic infections and antibody persistence. This longitudinal cohort study was aimed to evaluate SARS CoV2 ... ...

    Abstract Background: India has been amongst the most affected nations during the SARS CoV2 pandemic, with sparse data on country wide spread of asymptomatic infections and antibody persistence. This longitudinal cohort study was aimed to evaluate SARS CoV2 seropositivity rate as a marker of infection and evaluate temporal persistence of antibodies with neutralization capability and to infer possible risk factors for infection. Methods: Council of Scientific and Industrial Research, India (CSIR) with its more than 40 laboratories and centers in urban and semi urban settings spread across the country piloted the pan country surveillance. 10427 adult individuals working in CSIR laboratories and their family members based on voluntary participation were assessed for antibody presence and stability was analyzed over 6 months utilizing qualitative Elecysys SARS CoV2 specific antibody kit and GENScript cPass SARS CoV2 Neutralization Antibody Detection Kit. Along with demographic information, possible risk factors were evaluated through self to be filled online forms with data acquired on blood group type, occupation type, addiction and habits including smoking and alcohol, diet preferences, medical history and transport type utilized. Symptom history and information on possible contact and compliance with COVID 19 universal precautions was also obtained. Findings:1058 individuals (10.14%) had antibodies against SARS CoV2. A follow up on 346 seropositive individuals after three months revealed stable to higher antibody levels against SARS CoV2 but declining plasma activity for neutralizing SARS CoV2 receptor binding domain and ACE2 interaction. A repeat sampling of 35 individuals, at six months, revealed declining antibody levels while the neutralizing activity remained stable compared to three months. Majority of seropositive individuals (75%) did not recall even one of nine symptoms since March 2020. Fever was the most common symptom with one fourth reporting loss of taste or smell. Significantly associated risks for seropositivity (Odds Ratio, 95% CI, p value) were observed with usage of public transport (1.79, 1.43 to 2∙24, 2.81561x10-6), occupational responsibilities such as security, housekeeping personnel etc. (2.23, 1.92 to 2.59, 6.43969x10-26), non smokers (1.52, 1.16 to 1.99, 0.02) and non vegetarianism (1.67, 1.41 to 1.99, 3.03821x10-8). An iterative regression analysis was confirmatory and led to only modest changes to estimates. Predilections for seropositivity was noted with specific ABO blood groups; O was associated with a lower risk. Interpretation: In a first of its kind study from India, we report the seropositivity in a country wide cohort and identify variable susceptible associations for contacting infection. Serology and Neutralizing Antibody response provides much sought for general insights on the immune response to the virus among Indians and will be an important resource for designing vaccination strategies. Funding: Council of Scientific and Industrial Research, India (CSIR)
    Keywords covid19
    Language English
    Publishing date 2021-01-16
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.01.12.21249713
    Database COVID19

    Kategorien

  5. Article ; Online: Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2

    Naushin, Salwa / Sardana, Viren / Ujjainiya, Rajat / Bhatheja, Nitin / Kutum, Rintu / Bhaskar, Akash Kumar / Pradhan, Shalini / Prakash, Satyartha / Khan, Raju / Rawat, Birendra Singh / Tallapaka, Karthik Bharadwaj / Anumalla, Mahesh / Chandak, Giriraj Ratan / Lahiri, Amit / Kar, Susanta / Mulay, Shrikant Ramesh / Mugale, Madhav Nilakanth / Srivastava, Mrigank / Khan, Shaziya /
    Srivastava, Anjali / Tomar, Bhawna / Veerapandian, Murugan / Venkatachalam, Ganesh / Vijayakumar, Selvamani Raja / Agarwal, Ajay / Gupta, Dinesh / Halami, Prakash M / Peddha, Muthukumar Serva / Sundaram, Gopinath M / Veeranna, Ravindra P / Pal, Anirban / Agarwal, Vinay Kumar / Maurya, Anil Ku / Kumar Singh, Ran Vijay / Raman, Ashok Kumar / Anandasadagopan, Suresh Kumar / Karuppanan, Parimala / Venkatesan, Subramanian / Sardana, Harish Kumar / Kothari, Anamika / Jain, Rishabh / Thakur, Anupma / Parihar, Devendra Singh / Saifi, Anas / Kaur, Jasleen / Kumar, Virendra / Mishra, Avinash / Gogeri, Iranna / Rayasam, Geethavani / Singh, Praveen / Chakraborty, Rahul / Chaturvedi, Gaura / Karunakar, Pinreddy / Yadav, Rohit / Singhmar, Sunanda / Singh, Dayanidhi / Sarkar, Sharmistha / Bhattacharya, Purbasha / Acharya, Sundaram / Singh, Vandana / Verma, Shweta / Soni, Drishti / Seth, Surabhi / Vashisht, Shakshi / Thakran, Sarita / Fatima, Firdaus / Singh, Akash Pratap / Sharma, Akanksha / Sharma, Babita / Subramanian, Manikandan / Padwad, Yogendra / Hallan, Vipin / Patial, Vikram / Singh, Damanpreet / Tirpude, Narendra Vijay / Chakrabarti, Partha / Maity, Sujay Krishna / Ganguly, Dipyaman / Sarkar, Jit / Ramakrishna, Sistla / Kumar, Balthu Narender / Kumar, A Kiran / Gandhi, Sumit G. / Jamwal, Piyush Singh / Chouhan, Rekha / Jamwal, Vijay Lakshmi / Kapoor, Nitika / Ghosh, Debashish / Thakkar, Ghanshyam / Subudhi, Umakanta / Sen, Pradip / Chaudhury, Saumya Ray / Kumar, Rashmi / Gupta, Pawan / Tuli, Amit / Sharma, Deepak / Ringe, Rajesh P. / D, Amarnarayan / Kulkarni, Mahesh / Shanmugam, Dhanasekaran / Dharne, Mahesh S / Dastager, Syed G. / Joshi, Rakesh / Patil, Amita P. / Mahajan, Sachin N. / Khan, Abu Junaid / Wagh, Vasudev / Yadav, Rakeshkumar / Khilari, Ajinkya / Bhadange, Mayuri / Chaurasiya, Arvindkumar H. / Kulsange, Shabda E / Khairnar, Krishna / Paranjape, Shilpa / Kalita, Jatin / Sastry, G. Narahari / Phukan, Tridip / Manna, Prasenjit / Romi, Wahengbam / Bharali, Pankaj / Ozah, Dibyajyoti / Sahu, Ravi Kumar / Babu, Elapavalooru V.S.S.K. / Sukumaran, Rajeev / Nair, Aiswarya R / Kooloth-Valappil, Prajeesh / Puthiyamadam, Anoop / Velayudhanpillai, Adarsh / Chodankar, Kalpana / Damare, Samir / Madhavi, Yennapu / Aggarwal, Ved Varun / Dahiya, Sumit / Agrawal, Anurag / Dash, Debasis / Sengupta, Shantanu

    medRxiv

    Abstract: Background: India has been amongst the most affected nations during the SARS CoV2 pandemic, with sparse data on country wide spread of asymptomatic infections and antibody persistence. This longitudinal cohort study was aimed to evaluate SARS CoV2 ... ...

    Abstract Background: India has been amongst the most affected nations during the SARS CoV2 pandemic, with sparse data on country wide spread of asymptomatic infections and antibody persistence. This longitudinal cohort study was aimed to evaluate SARS CoV2 seropositivity rate as a marker of infection and evaluate temporal persistence of antibodies with neutralization capability and to infer possible risk factors for infection. Methods: Council of Scientific and Industrial Research, India (CSIR) with its more than 40 laboratories and centers in urban and semi urban settings spread across the country piloted the pan country surveillance. 10427 adult individuals working in CSIR laboratories and their family members based on voluntary participation were assessed for antibody presence and stability was analyzed over 6 months utilizing qualitative Elecysys SARS CoV2 specific antibody kit and GENScript cPass SARS CoV2 Neutralization Antibody Detection Kit. Along with demographic information, possible risk factors were evaluated through self to be filled online forms with data acquired on blood group type, occupation type, addiction and habits including smoking and alcohol, diet preferences, medical history and transport type utilized. Symptom history and information on possible contact and compliance with COVID 19 universal precautions was also obtained. Findings:1058 individuals (10.14%) had antibodies against SARS CoV2. A follow up on 346 seropositive individuals after three months revealed stable to higher antibody levels against SARS CoV2 but declining plasma activity for neutralizing SARS CoV2 receptor binding domain and ACE2 interaction. A repeat sampling of 35 individuals, at six months, revealed declining antibody levels while the neutralizing activity remained stable compared to three months. Majority of seropositive individuals (75%) did not recall even one of nine symptoms since March 2020. Fever was the most common symptom with one fourth reporting loss of taste or smell. Significantly associated risks for seropositivity (Odds Ratio, 95% CI, p value) were observed with usage of public transport (1.79, 1.43 to 2∙24, 2.81561x10-6), occupational responsibilities such as security, housekeeping personnel etc. (2.23, 1.92 to 2.59, 6.43969x10-26), non smokers (1.52, 1.16 to 1.99, 0.02) and non vegetarianism (1.67, 1.41 to 1.99, 3.03821x10-8). An iterative regression analysis was confirmatory and led to only modest changes to estimates. Predilections for seropositivity was noted with specific ABO blood groups; O was associated with a lower risk. Interpretation: In a first of its kind study from India, we report the seropositivity in a country wide cohort and identify variable susceptible associations for contacting infection. Serology and Neutralizing Antibody response provides much sought for general insights on the immune response to the virus among Indians and will be an important resource for designing vaccination strategies. Funding: Council of Scientific and Industrial Research, India (CSIR)
    Keywords covid19
    Language English
    Publishing date 2021-01-16
    Publisher Cold Spring Harbor Laboratory Press
    Document type Article ; Online
    DOI 10.1101/2021.01.12.21249713
    Database COVID19

    Kategorien

To top